Bottom Line First: What LLMs Do — and What They Don’t

In the workflow for LLM-assisted structural analysis of prokaryotic vault proteins, it is essential to separate what specialized algorithms handle from what LLMs handle. Sequence retrieval, domain comparison, de-redundancy clustering, cryo-EM particle picking and 3D reconstruction are primarily the domain of mature bioinformatics tools and dedicated image-processing algorithms. LLMs behave more like research agents: they turn candidate protein metrics into executable experimental plans, interpret purification and EM anomalies, suggest troubleshooting order, and produce review checklists.

A representative input/output example:

• Input: a candidate protein list containing domain E-values, sequence length, transmembrane segment predictions, solubility scores, adjacency of defense gene islands, database versions, and statistics cut-off dates.
• Output: expression construct recommendations, host and induction conditions, purification buffer combinations, cryo-EM sample-preparation priorities, anomaly troubleshooting suggestions, and a manual review checklist.
• Constraints: every conclusion must retain the original data, parameter versions, and review records; key structural models require independent validation and peer review.

1. Why Prokaryotic Vault Proteins Are Still Worth Solving

Vaults are a class of large, hollow protein complexes. Eukaryotic vaults are typically assembled from the major vault protein, small RNAs, and other accessory components; prokaryotic vault homologs are often structurally simpler, and whether they depend on RNA for assembly must be verified case by case. Unlike a single enzyme molecule, a vault behaves more like a structural container inside the cell, and its function does not always map onto one metabolic reaction — so its structural priority cannot be inferred from routine phenotypes alone.

Earlier vault research was carried out largely in mammalian cells and did produce near-atomic-resolution structures. Even so, functional boundaries, cross-species conservation, high-quality 3D structures of prokaryotic homologs, and a stable, reproducible sample source have remained in short supply. In other words, the problem is not simply “the structure is unclear.” The real difficulty is that giant complexes are hard to obtain as high-quality samples, and that there is a clear gap between sequence clues, expression and purification, structure determination, and biological interpretation.

For that reason, prokaryotic vault protein analysis is well suited to being organized as an engineering pipeline: data retrieval → candidate screening → automated experiments → rapid purification → cryo-EM reconstruction → manual review. LLMs can take on experiment design, data interpretation, and anomaly troubleshooting suggestions within that pipeline, but they cannot replace experimental verification.

2. From Sequence Search to a Candidate List: How Do You Filter for Expressible Proteins?

Prokaryotic systems offer a more suitable entry point for solving vault homolog structures. Bacterial and archaeal genomes are generally more compact, homologous genes are easier to identify, and the expression background is relatively well defined. But “found by search” is not the same as “expressible,” and it is certainly not the same as “solvable.” Before a candidate protein enters the lab, it should pass an engineered filter based on quantifiable metrics.

1. Sequence Retrieval and Homology Identification

Use version-controlled domain models for retrieval — for example, HMMER scans against Pfam, TIGRFAMs, or other validated vault major-protein-related HMMs. When writing up or reproducing the work, state the database name, version, statistics cut-off date, and terms of use, and do not treat database size as a permanent fact. If you cite data such as “an expansion in sequence count” or “growth in family membership,” add the primary database paper or release notes and label the year, DOI, or link.

2. Candidate Filtering Metrics and Thresholds

The table below gives an executable candidate filtering framework. The thresholds are examples; a real project must calibrate them against the target protein family, host expression behavior, and pilot data.

Metric	Recommended tool or method	Example criterion	Priority
Domain coverage	HMMER 3.4 scan against validated MVP/vault-related HMMs	Key domain E-value ≤ 1e-5, coverage ≥ 60%	High
Sequence integrity	Multiple sequence alignment, domain boundary check	No obvious truncation; key domains intact	High
Sequence length	ProtParam or a local script	Example range 600–1200 aa, adjusted per family	Medium
Transmembrane propensity	DeepTMHMM 1.0, TMHMM 2.0c	≤ 2 predicted TM segments; treat multi-pass candidates cautiously	High
Solubility prediction	DeepSol 1.0, PROSO II, etc.	Solubility score above a preset threshold, e.g. > 0.5	Medium-high
Toxicity/risk regions	ToxinPred 3.1, conserved domain annotation	No obvious high-risk motifs or complex post-translational modification dependencies	Medium
Defense island adjacency	Genome annotation, gene neighborhood analysis	Prioritize candidates adjacent to defense-related gene clusters	Medium
De-redundancy clustering	MMseqs2, CD-HIT	Cluster at 30%–40% similarity and keep representative sequences	High

3. Executable Screening Logic

The original pseudocode can be rewritten as the following executable flow, avoiding invented domain names:

Input: candidate protein sequence library, database versions, statistics cut-off date
Step 1: Scan validated vault-related HMMs with HMMER 3.4
  Keep sequences with E-value <= 1e-5
Step 2: Filter by length with a local script
  Keep sequences within the target range, e.g. 600-1200 aa
Step 3: Predict transmembrane segments with DeepTMHMM 1.0 or TMHMM 2.0c
  Discard sequences with more than 2 predicted TM segments
Step 4: Compute solubility scores with DeepSol 1.0 or PROSO II
  Keep high-scoring candidates; move low-scoring ones to a reserve pool
Step 5: Cluster with MMseqs2 or CD-HIT at 30%-40% similarity
  Keep one representative per cluster to avoid duplicate experiments
Step 6: LLM generates candidate ranking, expression construct suggestions,
  purification conditions, and a review checklist
  All suggestions require human confirmation before entering the experimental queue

The value of this step is not just automatically generating experimental plans. It converts screening criteria that used to depend on experience into a rule system that is traceable, reproducible, and iterable.

3. Candidate Expression and Purification: Why Can SEC Speed Up Giant Particle Purification?

Purifying giant protein complexes has always been the bottleneck. Traditional ultracentrifugation can separate target complexes by sedimentation coefficient, but the workflow is long and cannot support screening large numbers of candidates. Size-exclusion chromatography (SEC) is one of the more common fast purification approaches. Its principle is a sieving effect produced by porous media on particles of different sizes: small molecules enter the pores and take a longer migration path, while large particles are less likely to enter the pores and therefore elute earlier.

For large particles like vaults, which are tens of nanometers across, elution in a conventional SEC column is usually early, sometimes close to the void volume. That does not mean “large particles always come out first.” Sample concentration, buffer ionic strength, pH, load volume, column efficiency, and the aggregation state of the particles all affect elution behavior. More importantly, conventional SEC has limited ability to resolve intact particles from aggregates and partially degraded species, so sample homogeneity cannot be judged from a single main peak.

1. SEC Applicability Boundaries and Anomaly Troubleshooting

Anomaly	Possible cause	Troubleshooting and handling
Large peak appears only near the void volume	Particles too large, aggregation, column blockage, or sample viscosity too high	Centrifuge or filter first; use SEC-MALS or DLS to assess aggregation state; switch to a column better suited to large particles
Tailing peak shape	Non-specific adsorption, declining column efficiency, buffer mismatch	Adjust salt concentration or pH, or add a mild detergent; re-equilibrate the column
Multiple peaks	Incomplete assembly, degradation, aggregates, or nucleic acid contamination	Combine with negative-stain EM, mass spectrometry, or nucleic acid dye assays; optimize expression time and lysis conditions
Low peak area	Low expression, unstable particles, or sample precipitation	Change host, lower induction temperature, co-express chaperones, or adjust the lysis buffer
Poor reproducibility	Overloading, flow rate too high, sample batch variation	Run small-volume gradient experiments first, then scale up; record column ID, flow rate, buffer batch, and sample handling time

2. What Can LLMs Do in the Purification Step?

LLMs can help design small-volume gradient experiments, compare peak-shape changes under different salt concentrations, load volumes, and flow rates, and organize the results into a traceable experiment log. For example:

• Input: candidate protein ID, load amount, buffer formulation, UV 280 peak shape, SEC-MALS molecular weight estimate.
• Output: buffer combinations to try first, whether a column change is needed, whether negative staining or dynamic light scattering is advisable.
• Limits: LLMs cannot substitute for experimental evidence such as mass spectrometry, SEC-MALS, or negative-stain EM.

Given adequate load volume, column efficiency, and repeat-detection conditions, SEC can compress the separation of some giant particles from a multi-day traditional workflow down to hours; the actual speedup depends on sample amount, particle stability, column type, and detection method.

4. Cryo-EM: How Do You Turn Particles into a 3D Structure?

Once purification is complete, cryo-EM is usually the key method for solving giant protein complexes. The full workflow covers sample vitrification, low-dose imaging, image preprocessing, particle picking, 2D classification, 3D initial model generation, 3D refinement, and model validation. For large complexes like vaults, data analysis depends especially on understanding overall morphology, subunit arrangement, and orientation distribution.

1. Cryo-EM Workflow and Example Key Parameters

The parameters below are examples; actual values depend on the instrument, the sample, and particle properties:

1. Sample vitrification: rapidly freeze the protein suspension on a grid to form a thin layer of vitreous ice; optimize sample concentration, ice thickness, and blotting time.
2. Low-dose imaging: a 300 kV microscope is common; total electron dose is often in the 40–60 e-/Ų range, and pixel size usually needs adjusting for particle size and camera.
3. Image preprocessing: motion correction, contrast inversion, and rejection of defective regions.
4. Particle picking: dedicated algorithms can pre-screen by size, contrast, and edge features; LLMs can help check whether the selection rules are too permissive or too strict.
5. 2D classification: group by projection morphology and remove ice contamination, fragments, and anomalous particles.
6. 3D initial model generation: produce a low-resolution initial model; whether to impose symmetry must be verified, to avoid forcing false symmetry.
7. 3D refinement: iteratively optimize particle orientations and structural parameters; target particle counts often range from thousands to tens of thousands, depending on particle homogeneity and resolution goals.
8. Model building and validation: fit amino acid chains or domain models into the density map, assess resolution with common criteria such as FSC 0.143, and check geometric plausibility with tools such as MolProbity, Phenix, and Coot.

2. Where LLMs Help in the Cryo-EM Step

• Particle picking: help set size ranges, contrast thresholds, and exclusion rules.
• Low signal-to-noise images: flag whether dose needs increasing, pixel size needs adjusting, or data needs recollecting.
• 2D classification: help identify contaminating particles, anomalous projections, and class imbalance.
• Preferred orientation: use the particle angular distribution to flag clear directional gaps.
• Local resolution: flag low-confidence regions and remind the researcher to inspect subunit interfaces or flexible regions closely.
• Model building: propose local optimization suggestions based on sequence constraints and the density map.

It is worth stressing that LLMs cannot replace the experiment itself. The final structure must come from a reliable sample, reproducible data collection, and independent validation. Their value lies in reducing repetitive labor and helping researchers find the particle populations worth refining faster.

5. A Reproducible Loop: How Do You Record Parameters and Track Experiments?

Solving a prokaryotic vault protein structure is not just “getting one structure” — it is building a reproducible process. Focusing only on the final result makes it easy to overlook dependencies among samples, algorithms, and parameters. To keep the process traceable, retain three infrastructure modules directly tied to the pipeline described here:

1. Object storage and metadata records: store original sequences, candidate lists, experiment logs, EM images, and model files; record database versions, statistics cut-off dates, construct IDs, host, induction conditions, and buffer formulations.
2. Containerized compute: run sequence alignment, clustering, image preprocessing, and 3D reconstruction with pinned tool versions such as HMMER, MMseqs2, cryoSPARC, and RELION.
3. Job scheduling and log monitoring: schedule asynchronous tasks such as expression, purification, and EM data collection; record failed nodes, retry counts, and manual review comments.

In this loop, LLMs can generate experiment record templates, anomaly troubleshooting tables, and suggested logs, but the original evidence chain must be preserved. Reproducibility metrics should come from actual measurements — expression success rate, solubility rate, purification recovery, proportion of acceptable particles, final map resolution, and model validation results. Do not claim “improved reproducibility” without data to support it.

6. Risks and Boundaries: Which Conclusions Must Be Human-Verified?

Although LLMs and automated experiments can substantially shorten the cycle, their boundaries must be explicit:

1. Sequence homology does not guarantee a fully correct structure. Distant homologs may carry key insertions, deletions, or conformational differences.
2. Successful expression does not guarantee successful assembly. A soluble monomer does not mean a multi-subunit particle assembles correctly.
3. Normal purification peak shape does not guarantee a homogeneous sample. Some complexes may show metastable states, locally disordered regions, or a tendency to aggregate.
4. Cryo-EM data may show preferred orientation. If particles are observed along only a few directions, 3D reconstruction can produce pseudo-symmetry.
5. LLMs may return high-confidence but wrong suggestions, so human review and wet-lab verification must be retained.
6. Training data bias affects model judgment. If reference samples come mainly from a few classic systems, generalization to rare prokaryotic homologs needs careful assessment.
7. Protein sequence databases and image data both carry terms of use; comply with the license agreements when publishing or reproducing work.
8. Final structural models and biological interpretations should go through peer review; conclusions should not rest on an automated pipeline alone.

The reasonable approach is not to let an LLM reach conclusions on its own, but to have it take on verifiable, rollback-capable, traceable engineering tasks, with scientists confirming key hypotheses experimentally.

7. FAQ: The Five Questions Readers Ask Most

1. Can an LLM design an entire experiment on its own?

Not decisively. An LLM can generate expression construct, purification condition, sample-preparation priority, and anomaly troubleshooting suggestions, but every plan must be reviewed by researchers and governed by experimental results.

2. How do you judge whether a candidate protein is worth synthesizing?

Look first at domain coverage, sequence integrity, number of transmembrane segments, solubility prediction, de-redundancy representativeness, and defense island adjacency. Sequence similarity alone is not enough; combine it with small-scale expression tests and purification pilot experiments.

3. Can SEC alone prove particle homogeneity?

No. SEC can indicate particle size range and aggregation tendency, but judging homogeneity should combine SEC-MALS, dynamic light scattering, negative-stain EM, mass spectrometry, or functional assays.

4. How do you avoid pseudo-symmetry in cryo-EM?

Check the particle orientation distribution and avoid forcing symmetry when orientation bias is obvious; after refinement, inspect the FSC curve, local resolution, subunit arrangement, and model geometric plausibility.

5. How do you keep results traceable?

Record database versions, statistics cut-off dates, candidate screening thresholds, construct sequences, host, induction conditions, purification buffers, EM parameters, processing software versions, and manual review comments. All key files should go into traceable object storage or an electronic lab record system.

8. Closing: A New Paradigm for Giant Protein Structure Determination

The difficulty of prokaryotic vault protein analysis is not only the size of the structure, but the fact that it spans sequence mining, candidate screening, expression and purification, cryo-EM, and structure modeling. No single technique can solve the whole problem independently. The value of LLM assistance is that it organizes scattered experimental decisions, data interpretation, and anomaly troubleshooting into a continuously iterating system, letting researchers close the loop from candidate protein screening → sample preparation → EM observation → model validation faster.

Going forward, this kind of approach can extend to more large protein complexes, membrane protein complexes, viral capsids, and engineered synthetic nanocontainers. What truly drives change is not any single algorithm, but the coordination among sequence mining, experimental automation, purification engineering, and structure determination. For structural biology, that is not merely a speed gain — it is a restructuring of how research is done.